Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Othmane Jadi, Hancong Tang, Kelly Shea Olsen, Steven Vensko, Qianqian Zhu, Yiwen Wang, Christopher A. Haiman, Loreall Pooler, Xin Sheng, Guy Brock, Amy Webb, Marcelo C Pasquini, Philip L. McCarthy, Stephen R. Spellman, Theresa E. Hahn, Benjamin G. Vincent, Paul M. Armistead, Lara E. Sucheston-Campbell

Blood (2022) 140 (Supplement 1): 668–670.

DOI: https://doi.org/10.1182/blood-2022-167165

Published: 2022

Journal Articles

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Joseph Rimando, Leslie Cope, Karen McKinnon, Benjamin G. Vincent, Sergio Rutella, Joshua F. Zeidner, Jonathan S. Serody, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 6314–6315.

DOI: https://doi.org/10.1182/blood-2022-165458

Published: 2022

Journal Articles

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Blood (2022) 140 (Supplement 1): 4472–4474.

DOI: https://doi.org/10.1182/blood-2022-167018

Published: 2022

Journal Articles

Population Distribution of GvL and GvH Minor Histocompatibility Antigens

Kelly Shea Olsen, MSc, Hancong Tang, MS, Junke Wang, MS, Sarah Entwistle, MSc, Dante S. Bortone, PhD, Steven Vensko, PhD, Loreall Pooler, Xin Sheng, MS, Christopher Haiman, David Van Den Berg, PhD, Stephen R. Spellman, MS, Theresa E. Hahn, PhD, Paul M. Armistead, MD PhD, Lara E. Sucheston-Campbell, PhDMS, Benjamin G. Vincent, MD

Blood (2020) 136 (Supplement 1): 23–25.

DOI: https://doi.org/10.1182/blood-2020-141120

Published: 2020

Journal Articles

Associations of Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation with Number of Predicted Class II Restricted mHA

Othmane Jadi, BS,BA, Hancong Tang, MS, Junke Wang, MS, Dante Bortone, PhD, Steven Vensko, PhD, Loreall Pooler, Xin Sheng, MS, Christopher A. Haiman, PhD, David Van Den Berg, PhD, Stephen R. Spellman, MS, Marcelo C. Pasquini, MDMS, Theresa E. Hahn, PhD, Paul M. Armistead, MD PhD, Benjamin G. Vincent, MD, Lara E. Sucheston-Campbell, PhDMS

Blood (2020) 136 (Supplement 1): 2.

DOI: https://doi.org/10.1182/blood-2020-142017

Published: 2020

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

DOI: https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

DOI: https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

DOI: https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Blood (2018) 132 (Supplement 1): 4054.

DOI: https://doi.org/10.1182/blood-2018-99-116608

Published: 2018

Journal Articles

Evidence for Role of Enzymatic Operations in Shared T-Cell Receptors

Mark Woodcock, MD, Adam Buntzman, PhD, Benjamin G. Vincent, MD

Blood (2018) 132 (Supplement 1): 3703.

DOI: https://doi.org/10.1182/blood-2018-99-118884

Published: 2018

Journal Articles

Bim regulates the survival and suppressive capability of CD8 + FOXP3 + regulatory T cells during murine GVHD

Kimberle Agle, Benjamin G. Vincent, Clint Piper, Ludovic Belle, Vivian Zhou, Warren Shlomchik, Jonathan S. Serody, William R. Drobyski

Blood (2018) 132 (4): 435–447.

DOI: https://doi.org/10.1182/blood-2017-09-807156

Published: 2018

Includes: Supplemental data

Journal Articles

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Matthew C. Foster, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Benjamin G. Vincent, MD, Melissa Matson, AGPCNP-BC, Karen McKinnon, PhD, Shannon Reisdorf, BS, Jack Zhang, RN, Will Pulley, BA, Hyman Muss, MD, Anastasia Ivanova, PhD, Joshua F Zeidner, MD

Blood (2017) 130 (Supplement 1): 2631.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2631.2631

Published: 2017

Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD

Blood (2017) 130 (Supplement 1): 1349.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349

Published: 2017

Journal Articles

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Charlotte McIlwaine Story, BS, MD, Jefferson L. Lansford, BS, Dominic T. Moore, MPH, MS, Chang Xu, Benjamin G. Vincent, MD, Paul M. Armistead, MD PhD, Marcie L. Riches, MDMS

Blood (2017) 130 (Supplement 1): 1987.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1987.1987

Published: 2017

Journal Articles

Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease

Benjamin G. Vincent, MD, Kimberle A. Agle, PhD, Ludovic Belle, PhD, Vivan Zhou, PhD, Clint Piper, BS, Warren D Shlomchik, MD, Jonathan S Serody, MD, William R. Drobyski, MD

Blood (2017) 130 (Supplement 1): 209.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.209.209

Published: 2017

Journal Articles

Identification of Leukemia Associated Minor Histocompatibility Antigens through Computational Prediction and Targeted Mass Spectrometry

Jefferson L. Lansford, BS, Udara Dharmasiri, PhD, Shengjie Chai, BS, Sally A. Hunsucker, PhD, Dante S. Bortone, PhD, James E. Keating, BS, Ian M. Schlup, Gary L. Glish, PhD, Edward J. Collins, PhD, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD, Paul M. Armistead, MD PhD, Benjamin G. Vincent, MD

Blood (2017) 130 (Supplement 1): 207.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.207.207

Published: 2017

Journal Articles

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD

Blood (2017) 130 (19): 2131–2145.

DOI: https://doi.org/10.1182/blood-2017-05-782466

Published: 2017

Includes: Supplemental data

Journal Articles

T-cell expression of AhR inhibits the maintenance of pT reg cells in the gastrointestinal tract in acute GVHD

Trisha A. Dant, Kaifeng L. Lin, Danny W. Bruce, Stephanie A. Montgomery, Oleg V. Kolupaev, Hemamalini Bommiasamy, Lisa M. Bixby, John T. Woosley, Karen P. McKinnon, Frank J. Gonzalez, Bruce R. Blazar, Benjamin G. Vincent, James M. Coghill, Jonathan S. Serody

Blood (2017) 130 (3): 348–359.

DOI: https://doi.org/10.1182/blood-2016-08-734244

Published: 2017

Includes: Supplemental data

Journal Articles

Integrated In Silico Prediction of Minor Histocompatibility Antigen Peptides in HLA-Matched Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Jefferson L. Lansford, Shengjie Chai, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD, Paul M. Armistead, MD PhD, Benjamin G. Vincent, MD

Blood (2016) 128 (22): 3352.

DOI: https://doi.org/10.1182/blood.V128.22.3352.3352

Published: 2016

Journal Articles

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Danny W Bruce, PhD, Heather E Stefanski, MD PhD, Benjamin G. Vincent, MD, Trisha Dant, BS, Shannon Reisdorf, BS, Hemamalini Bommiasamy, PhD, David Serody, Justin E Wilson, PhD, Karen McKinnon, PhD, Warren D Shlomchik, MD, Paul M. Armistead, MD PhD, Jenny PY Ting, PhD, John T Woosley, MD PhD, Dietmar MW Zaiss, PhD, Bruce R. Blazar, MD, Andrew NJ McKenzie, PhD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2016) 128 (22): 1155.

DOI: https://doi.org/10.1182/blood.V128.22.1155.1155

Published: 2016

NARROW

Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Population Distribution of GvL and GvH Minor Histocompatibility Antigens

Associations of Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation with Number of Predicted Class II Restricted mHA

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Evidence for Role of Enzymatic Operations in Shared T-Cell Receptors

Bim regulates the survival and suppressive capability of CD8 + FOXP3 + regulatory T cells during murine GVHD

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Class I HLA Peptide Epitope Binding Efficiency Has No Impact on Graft Vs. Host Disease Incidence Following Allogeneic Hematopoietic Cell Transplantation

Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease

Identification of Leukemia Associated Minor Histocompatibility Antigens through Computational Prediction and Targeted Mass Spectrometry

An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD

T-cell expression of AhR inhibits the maintenance of pT reg cells in the gastrointestinal tract in acute GVHD

Integrated In Silico Prediction of Minor Histocompatibility Antigen Peptides in HLA-Matched Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only